Matrix metalloproteinase-9 (MMP-9) has been implicated in airways injury in chronic obstructive pulmonary disease (COPD). Osteoporosis is common in patients with COPD, and MMP-9 is an indicator of activated osteoclasts. We hypothesized that circulating MMP-9 would be related to bone mineral density (BMD) in COPD. We explored the relationship between MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1 and -2, and BMD status in patients with COPD. A total of 70 clinically stable patients with confirmed COPD and 39 control subjects underwent spirometry, dual-energy x-ray absorptiometry to determine BMD, and venous sampling for measurement of cytokines and MMP-9 and TIMP-1 and -2. In patients, circulating MMP-9 was increased: mean (SD) 38.5 (2.2) compared with control subjects 20.1 (2.0) ng/mL, P < 0.001, whereas TIMP-1 and -2 were not different. In the patients, MMP-9 was greater in those with osteoporosis, compared with those with osteopenia, no bone disease or control subjects, and patients with osteopenia had greater MMP-9 than control subjects. The adjusted receiver operating characteristics curve area for MMP-9 detecting osteoporosis was 0.86. Patients had elevated systemic inflammatory mediators compared with control subjects, but these were unrelated to bone status. Increased circulating MMP-9 in patients with COPD was related to the presence of osteoporosis and not to lung function. MMP-9 may be a biomarker of increased bone resorption. Chronic Respiratory Disease 2009; 6: 81-87
Introduction
The systemic complications associated with chronic obstructive pulmonary disease (COPD) include osteoporosis, loss of skeletal muscle mass and function, systemic inflammation, catabolic intermediary metabolism, impaired glucose tolerance, and an increased risk of cardiovascular disease, all of which cause considerable morbidity and mortality. [1] [2] [3] [4] [5] We have previously reported a high prevalence of unsuspected osteoporosis in patients with COPD who were not receiving long-term oral corticosteroid therapy. 2 In the general population, age, smoking, gender, vitamin D deficiency, hypogonadism, reduced physical activity, and sarcopenia are recognized factors for osteoporosis. In COPD, the same factors are likely to be active with additional effects from oral corticosteroid usage, chronic systemic inflammation, and catabolic intermediary metabolism, though the importance of the individual contributions is unknown. 2, [6] [7] [8] [9] [10] [11] We previously reported an association between a low fat-free mass (FFM) and bone thinning, which may occur through common proteolytic mechanisms in both tissues. Thus, the protein catabolic state in COPD may cause preferential loss of protein rich tissues, such as skeletal muscle and bone connective tissue with consequent bone mineral reduction. 1, 2, 12 The protease-antiprotease theory of the development of COPD implicates an imbalance between antiproteases, such as α-1-antitrypsin and neutrophil elastase leading to unopposed proteolysis. Recently, matrix metalloproteinases (MMPs), a family of 24 zinc-dependent endopeptidases which are important in the turnover of the extracellular matrix in various tissues including the lungs, and their balance with tissue inhibitors of metalloproteinases (TIMPs) have been implicated in both animal models and patients with COPD. [13] [14] [15] [16] [17] [18] [19] [20] [21] Respiratory tract cells including bronchial epithelial cells, clara cells, fibroblasts, macrophages, lymphocytes, and neutrophils are capable of producing MMP-9 in various disease states. 20, 21 Of the MMPs, MMP-9 a 92 kDa gelatinase has been implicated in alveolar destruction, increased permeability, and elastin degradation in animal models. 13, 14 Detectable circulating levels of MMPs and TIMPs have been reported in both non-COPD subjects and in patients with COPD, where MMP-9 may be related to the severity of lung disease. [22] [23] [24] In addition to lung disease, circulating MMPs in COPD may also reflect the development of atherosclerosis and increased bone protein turnover. In the later phases of atheromatous maturation, MMPs have been suggested to have a role in plaque erosion and rupture. 25 In endochondral ossification, MMP-9 and MMP-13 have important regulatory functions in bone turnover. In all species thus far studied, MMP-9 is associated with the activation of osteoclasts, osteoclasts being involved in bone resorption. The precise role of MMP-9 in bone homeostasis is unknown, but its absence in the MMP-9 null mouse leads to failure of controlled bone growth. 26, 27 We hypothesized that MMP-9 would be associated with bone thinning, reflected by increased circulating concentrations. We studied patients with COPD over a wide range of severity of airways obstruction to determine the relationship between circulating MMP-9 and the inhibitors: TIMP-1 and -2 and their relationship to the presence of bone thinning, and to explore the potential for circulating MMP-9 as a biomarker of bone disease in COPD.
Methods

Subjects
Patients with a proven diagnosis of COPD (n = 70) were recruited when clinically stable: no antibiotics or oral corticosteroids nor increase in respiratory symptoms in the last month. 28 We also studied 39 control subjects, free of respiratory disease. All were Caucasian. Exclusion criteria for all subjects were neoplastic, metabolic or inflammatory disease, cardiac failure, current ischemic symptoms, chronic oral corticosteroid treatment, or use of weightlowering drugs. We excluded subjects with known osteoporosis or on treatment such as bisphospho-nates as they would be likely to interfere. All subjects gave written, informed consent, and the study had Local Research Ethics Committee approval.
Anthropometry and lung function
Height and weight (Seca, Hamburg, Germany) were determined with the patient bare foot and in lightweight indoor clothing. From this, the body mass index (BMI) was calculated (kg/m 2 ). Spirometry (Vitalograph, Bucks, UK) was performed with abstinence from short-acting inhaled bronchodilators for 6 hours and long-acting bronchodilators for 12 hours. Forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC), and their ratio (FEV 1 /FVC) were determined in all subjects from the best of three valid attempts. Patients were subdivided according to a FEV 1 < 50% predicted (GOLD III and IV) or >50% predicted (GOLD I and II). 28 
Dual-energy x-ray absorptiometry
Whole-body composition and bone mineral density (BMD) of both the lumbar spine and hip were determined using the Hologic Discovery (Hologic Inc., Waltham, Massachusetts, USA). The FFM was determined and standardized for body habitus using a height squared ratio-fat-free mass index (FFMI). The BMD was presented as absolute figures and as a T-score, the SD from a young, gender-specific reference mean BMD to determine the presence of osteoporosis or osteopenia. The BMD was expressed in absolute units (g per square cm) and as a T-score (the number of reference population SDs from the reference mean value for a young adult of the same gender) to determine the presence of osteoporosis or osteopenia. 29 
Serum assays
High-sensitivity MMP-9 (pro-MMP-9), TIMP-1 and -2 levels were determined by sandwich enzyme-linked immunosorbent assay (ELISA) (Amersham Biosciences, Little Chalfont, Bucks, UK) on batched samples with the assayist blind to the subjects' identity. The coefficient of variation was <10% for intra-and inter-assay variations, and the sensitivity was 0.6 ng/mL for MMP-9, 1.25 ng/mL for TIMP-1, and 3 ng/mL for TIMP-2. No subject had a result close to the sensitivity. Interleukin 6 (IL-6) and tumor necrosis factor soluble receptors (TNF-α sr1 and 2) were measured by ELISA (R&D Systems Europe, UK) as previously reported. 2, 3 Statistics Data analysis was by Statistical Package for Social Science (SPSS) version 11.0 (SPSS Inc, Chicago, Illinois, USA). Results are presented as the arithmetic or geometric mean if non-normally distributed after log 10 transformation and SD. Analyses included the chi-square (χ 2 ) test, independent t-test, one-way analyses of variance with a post-hoc Tukey's test, Pearson's correlation, and logistic and multiple stepwise linear regressions. A P < 0.05 was considered significant. The ability to discriminate between patients with and without osteoporosis was quantified by using the area under the receiver operating characteristics curve (ROC area). The ROC area is a suitable measure to summarize the discriminative power of a diagnostic model and can range from 0.5 (no discrimination) to 1.0 (perfect discrimination). A value of 0.7-0.8 is considered to represent reasonable discrimination and values >0.8 suggest good discrimination.
Results
The demographics are presented in Table 1 . Osteoporosis was present in 19 (27%) of the patients and 5 (13%) of the controls. There was more bone thinning (osteoporosis and osteopenia) in patients compared with control subjects, χ 2 , P = 0.002 (Table 1) .
Of the 70 patients, 32 patients had a FEV 1 > 50% predicted and 38 patients had a FEV 1 < 50% predicted. There was a greater prevalence of bone disease in those with more severe airways obstruction: osteoporosis n = 13 (34%), osteopenia n = 21 (55%), than milder airways obstruction: osteoporosis n = 6 (19%), osteopenia n = 15 (47%).
The patients had a greater circulating MMP-9: geometric mean (SD) 38.5 (2.2) compared with control subjects 20.1 (2.0) ng/mL, P < 0.001. There was no difference between patients and control subjects for TIMP-1 and -2 ( Table 2 ). Log 10 MMP-9 was not related to either FEV 1 or FEV 1 % predicted, P = 0.2.
Eighteen patients and eight control subjects either reported myocardial infarct or ischemic event >5 years ago (n = 2 control subjects, 9 patients) and/ or hypertension (n = 7 control subjects, 12 patients). No patient had current ischemic symptoms. The MMP-9 in these subjects collectively and in the patients and control subjects separately was not different to those without a history of cardiovascular disease or hypertension (in all subjects P = 0.756; in control subjects P = 0.456; in patients P = 0.73). Patients still had a greater circulating MMP-9 than control subjects in the smaller subgroup without a cardiac history, P < 0.001. Given that none of the subjects had current symptoms and there was no difference in the MMP-9, all of the subjects have been analyzed together.
Bone disease and osteoporosis
In the patients, circulating MMP-9 was greater in those with osteoporosis: 51.29 (2.33) ng/mL compared with controls, P < 0.001; or those patients with either a normal BMD: 24.0 (1.8), P < 0.001 or osteopenia: 28.1 (2.4) ng/mL, P < 0.02 ( Figure 1 ). Control subjects had a lower MMP-9 compared with either those patients with osteopenia (P < 0.03) or osteoporosis (P < 001) but were not different to patients with normal BMD (Figure 1 ). In the smaller group of patients free of cardiovascular disease, MMP-9 was elevated in the patients with osteoporosis compared with those without, P = 0.015. Circulating MMP-9 was related to BMD at the lumbar (r = −0.36, P < 0.001) and hip (r = −0.29, P < 0.01) sites, in the whole population and in the patients separately: lumbar (r = −0.36, P < 0.01) and hip (r = −0.23, P = 0.05).
In patients, logistic regression, with osteoporosis as the dependent variable and the independent variables: log 10 MMP-9, age, gender, log 10 IL-6, FFMI, BMI, FEV 1 , smoking pack years, revealed both FFMI: odds ratio (OR [95% CI]) 0.64 (0.47, 0.87) and log 10 MMP-9: OR (95% CI) 6.23 (1.03, 37.64) as the only relevant variables, P < 0.05. Neither FFMI nor log 10 MMP-9 were significant variables of osteoporosis in control subjects.
In patients, linear regression with BMD lumbar spine as the dependent variable and the same variables as above, the adjusted r 2 was 37.2% with only FFMI (33.9%) and log 10 MMP-9 (goes to 37.2%) being significant. For BMD hip, the r 2 was 57.7% with only FFMI being significant.
The utility of log 10 MMP-9 in detecting osteoporosis had a ROC of 0.86 in patients alone and 0.84 in all subjects, adjusted for age, gender, smoking pack years, FEV 1 % predicted, inhaled corticosteroid, and FFMI ( Figure 2 ). This indicates good discrimination. Unadjusted log 10 MMP-9 had an ROC of 0.73 for both patients alone and for all subjects. Log MMP-9 (95% CI) COPD patients Figure 1 Matrix metalloproteinase (MMP)-9 in patients according to bone status and in control subjects. Mean and 95% confidence interval (CI). The three bone groups are patient subgroups. 
-Specificity
Inflammatory mediators
Circulating IL-6 (P < 0.001), TNF-α srI (P < 0.01) and TNF-α srII (P < 0.001) were greater in patients than control subjects ( Table 2 ). In patients alone, none of the log 10 transformed cytokines related to MMP-9.
Discussion
Circulating levels of MMP-9 were increased in patients with COPD compared with healthy non-COPD control subjects. This increase was not associated with a parallel change in circulating TIMP-1 and -2. Within the patient group, the MMP-9 increase was associated with loss of BMD, both osteopenia and osteoporosis, being greatest in those patients with osteoporosis and was independent of lung function parameters.
A number of MMPs have been implicated in the development of COPD, [13] [14] [15] but it is unknown which MMPs and their relationship to TIMPs and other components of the inflammatory response are important in the injury process. It has been suggested that MMP-9 may have a specific role in man and gene studies support the involvement of MMP-9 and MMP-12, 18,20,21 but it is less clear what circulating MMPs indicate in COPD. [22] [23] [24] Thus, interpretation of our data require caution, but taken in the context of the current literature and our stratification of patients on the basis of the presence or absence of bone disease it is possible to draw some conclusions. Considered as a whole group, our patients had increased circulating MMP-9 compared with control subjects, which suggests the increase in MMP-9 could be related to the local pulmonary inflammatory state and may represent an overspill from the lungs. Viewed this way, the data supports reports of increased MMP-9 in COPD, but that only applies if the data are considered irrespective of the patients' bone status as in other studies. 24 If the MMP-9 we detected was simply due to overspill from pulmonary inflammation into the circulation, there should have been an increase in a more severe airways obstruction in COPD group. This lack of association with lung function in COPD patients supports the findings of Higashimoto, et al. 23 Elevated MMP-9 could be a reflection of changes in the circulation and be linked to neutrophil activation occurring with recruitment to the lung, however, an equally likely circulating source is the monocyte, which has been shown to release increased amounts of MMP-9 in COPD. 30 An alternative possibility is that the presence of atherosclerosis and arterial stiffness is the source of MMP-9, which has been implicated in isolated systolic hypertension. 31 However, active cardiovascular disease was ruled out in our patients by the subanalysis of the group with a history of ischemic heart disease or hypertension, which revealed no increase in this group apart from those subjects with osteoporosis.
Our use of strictly defined bone thinning demonstrated a stepwise increase in MMP-9 in patients with osteopenia and osteoporosis compared with that in the control subjects. This relationship is likely to reflect the increased number of active osteoclasts associated with increased bone resorption in patients with COPD as MMP-9 is secreted by osteoclasts and their progenitor cells, monocytes, which have enhanced spontaneous secretion of MMP-9 in COPD. 30 Although, MMP-9 (gelatinase B) is only a weak collagenase and is unlikely to be responsible for collagen-1 breakdown in bone connective tissue, it has a role in bone remodeling and turnover and is essential for recruitment of preosteoclasts into bone and their local migration into the diaphysis. 32 Expression of messenger RNA in osteoporotic bone tissue is increased compared with normal bone and in parallel, bisphosphonates inhibit a number of MMPs in vitro. 33, 34 We were unable to demonstrate any relationship between MMP-9 and circulating inflammatory mediators, though the evidence of a link of osteoporosis in other chronic systemic inflammatory states, such as chronic heart failure and cystic fibrosis, is well reported. 34, 35 A demonstrable link might be expected as inflammation has been implicated in the pathophysiology of postmenopausal osteoporosis and physiological bone remodeling is regulated through interactions of systemic hormones and local cytokines, 8, 36 but circulating inflammatory mediators may not reflect the activity of those acting locally in bone. 37 Although loss of BMD is common in COPD, opinions as to which patients with COPD require a dual-energy x-ray absorptiometry (DXA) scan are divided. Additionally, it is unclear what the appropriate response should be to finding osteopenia or osteoporosis in patients with mild airways obstruction who are not receiving contributory medication, especially if they are not postmenopausal women. A high probability predictive biomarker of bone disease would be useful. Our finding of a clear separation between patients with accepted bone mineral loss and control subjects for levels of circulating MMP-9, a potential pathophysiological factor in bone disease, suggests MMP-9 might be a useful predictor of the need to DXA scan patients with COPD. This suggestion is supported by the ROC curve score of 0.84 for MMP-9-reflecting a good ability to meet such a role, but further longitudinal studies are needed, particularly if it is to be applied to monitor response to therapy and disease progression.
Limitations of this study
We did not measure the levels of MMPs in the airways compartment, but there is an abundance of evidence to support the presence of a range of MMP enzymes being involved. [15] [16] [17] [18] [19] [20] We measured MMP-9 mass rather than activity, but activity in serum has been shown to be closely related to quantity. 23 Although information is available for current and past inhaled corticosteroid therapy, prior oral corticosteroid therapy by the patient could not be corroborated by reviewing general practitioner records. This study was conducted in a small population of patients who were well described. However, further longitudinal studies in larger populations are required to clarify the potential use of MMP-9 as a bone resorption biomarker in COPD and whether it is elevated in non-COPD patients with osteoporosis. A low prevalence in our control population limited any analysis of its utility here.
In conclusion, we have demonstrated in a group of patients with COPD covering a wide range of severity of airways obstruction that circulating MMP-9 is increased compared with control subjects. The greatest levels were in those patients with osteoporosis. Osteoporosis in this group of patients is extremely prevalent but often occult. MMP-9 appears to reflect increased bone resorption by being a marker of osteoclast activation.
